Payment overview · 2025
General Payments
$152.71
7 reported records · 4 companies
Healthcare provider profile · identity verified
James Brian Wilhite, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUSCALOOSA, AL · NPI 1043329808
Verified facts
What the public records show
CMS Open Payments records show James Brian Wilhite, M.D. received $152.71 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.02 | 35.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.96 | 34.0% | 2 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $24.23 | 15.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.50 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.71 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.02 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.02 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.96 | 2 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 120 |
| Losartan Potassium | Losartan Potassium | 285 | 72 |
| Celecoxib | Celecoxib | 275 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 71 |
| Clonazepam | Clonazepam | 236 | 35 |
| Gabapentin | Gabapentin | 193 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 30 |
| Omeprazole | Omeprazole | 186 | 52 |
| Eliquis | Apixaban | 162 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 35 |
| Potassium Chloride | Potassium Chloride | 153 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 44 |
| Alprazolam | Alprazolam | 142 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 40 |
| Azithromycin | Azithromycin | 135 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 20 |
| Cefuroxime | Cefuroxime Axetil | 134 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 41 |
| Xarelto | Rivaroxaban | 125 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 33 |
| Trazodone Hcl | Trazodone Hcl | 120 | 26 |
| Simvastatin | Simvastatin | 116 | 31 |
| Tramadol Hcl | Tramadol Hcl | 109 | 27 |
| Famotidine | Famotidine | 103 | 32 |
| Furosemide | Furosemide | 103 | 23 |
| Carvedilol | Carvedilol | 101 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 21 |
| Methocarbamol | Methocarbamol | 99 | 31 |
| Temazepam | Temazepam | 99 | 16 |
| Synthroid | Levothyroxine Sodium | 97 | 20 |
| Ozempic | Semaglutide | 86 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 21 |
| Glimepiride | Glimepiride | 78 | 22 |
| Meloxicam | Meloxicam | 78 | 22 |
| Allopurinol | Allopurinol | 77 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 62 |
| Bupropion Xl | Bupropion Hcl | 72 | 15 |
| Sertraline Hcl | Sertraline Hcl | 72 | 19 |
| Montelukast Sodium | Montelukast Sodium | 70 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 16 |
| Lorazepam | Lorazepam | 67 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 22 |
| Irbesartan | Irbesartan | 62 | 12 |
| Prednisone | Prednisone | 62 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 19 |
| Myrbetriq | Mirabegron | 61 | 11 |
| Metformin Hcl Er | Metformin Hcl | 59 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 13 |
| Lisinopril | Lisinopril | 58 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 21 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 17 |
| Latanoprost | Latanoprost | 54 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Methylprednisolone | Methylprednisolone | 53 | 43 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 51 | 34 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 50 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Febuxostat | Febuxostat | 46 | suppressed |
| Ofloxacin | Ofloxacin | 46 | 29 |
| Torsemide | Torsemide | 45 | 16 |
| Levofloxacin | Levofloxacin | 44 | 33 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 11 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Metformin Hcl | Metformin Hcl | 39 | 12 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 31 |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Multaq | Dronedarone Hcl | 31 | suppressed |
| Metronidazole | Metronidazole | 30 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Dutasteride | Dutasteride | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 13 |
| Atenolol | Atenolol | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Dexamethasone | Dexamethasone | 19 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Famciclovir | Famciclovir | 17 | 13 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.71 · 7 records | Amgen Inc. | GEMTESA, OTEZLA, Photrexa Viscous and Photrexa, REPATHA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error